Oncological outcomes of laparoscopic nephroureterectomy versus open radical nephroureterectomy for upper tract urothelial carcinoma: An European Association of Urology Guidelines systematic review

Peyronnet, B.; Seisen, Thomas; Escrig, J.L. Domínguez; Bruins, H.M.; Yuan, Chen; Lam, Thomas; MacLennan, Sara; N’Dow, James; Babjuk, M.; Comperat, E.; Zigeuner, Richard; Sylvester, R. J.; Burger, Maximilian; Mostafid, Hugh; Gontero, Paolo; Palou, Juan; Shariat, S.F.; Rouprêt, Morgan

doi:10.1016/s1569-9056(18)32045-1

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Open radical cystectomy is still the most common used approach of cystectomy in clinical practice. However, the complication of surgical procedure has a high perioperative complication rate and significant mortality [ 1 – 3 ]. In the past decades, the development of laparoscopic instruments and technology became mature, making laparoscopic as a new treatment option for patients with bladder cancer.…”

Section: Introductionmentioning

confidence: 99%

Clinical outcome of laparoscopic versus robot-assisted radical cystectomy for patients with bladder cancer: a retrospective study

Bai

Zheng

et al. 2021

BMC Surg

View full text Add to dashboard Cite

Background With the development of minimally invasive surgery technology, patients with bladder cancer are increasingly receiving laparoscopic radical cystectomy (LRC) or robotic-assisted radical cystectomy (RARC) treatment. The main purpose of this study was to compare the long-term outcomes of bladder cancer patients treated with LRC versus RARC. Methods A retrospective study to identify patients with clinical stage Ta/T1/Tis to T3 bladder cancer who underwent RARC or LRC has been performed. The perioperative outcome, recurrence, and overall survival (OS) of the two surgical methods were compared. Results 218 patients were identified from March 2010 to December 2019 in our department, which including 82 (38%) patients who received LRC and 136 (62%) patients who received RARC. There was no significant difference between the two groups in terms of lymph node collection, lymph node positive rate, resection margin positive rate, and postoperative pathological staging. Compared with the LRC group, patients in the RARC group had a median estimated blood loss (180 vs. 250 ml; P = 0.02) and reduced complications at 90 days postoperatively (30.8% vs. 46.3%; P = 0.01). Recurrence, all-cause death, and cancer-specific death occurred in 77 (35%), 55 (25%), and 39 (18%) patients, respectively. The 5-year OS rate was 54.63% and 54.65% in the RARC and LRC group (P > 0.05). The 5-year cancer-specific survival (CSS) rate was 73.32% and 61.55% in RARC and LRC group (P > 0.05). There was no significant difference in OS [hazard ratio (HR) 1.083, 95% confidence interval (CI) 0.626–1.874; P = 0.78], and CSS (HR 0.789, 95%CI 0.411–1.515; P = 0.61) between two groups. Conclusions Both RARC and LRC were safe and effective with a similar long-term clinical outcomes. Moreover, RARC had significantly lower median estimated blood loss and reduced postoperative complications.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical outcome of laparoscopic versus robot-assisted radical cystectomy for patients with bladder cancer: a retrospective study

Bai

Zheng

et al. 2021

BMC Surg

View full text Add to dashboard Cite

show abstract

Radiation Therapy in Carcinomas of the Renal Pelvis and the Ureters

Chatzikonstantinou

Tselis

2018

Radiation Oncology

View full text Add to dashboard Cite

Recent advances in upper tract urothelial carcinomas: From bench to clinics

2018

View full text Add to dashboard Cite

Urothelial carcinoma in the upper tract is rare and often discussed separately. Many established risk factors were identified for the disease, including genetic and external risk factors. Radiographic survey, endoscopic examination and urine cytology remained the most important diagnostic modalities. In localized upper tract urothelial carcinomas, radical nephroureterectomy with bladder cuff excision are the gold standard for large, high‐grade and suspected invasive tumors of the renal pelvis and proximal ureter, whereas kidney‐sparing surgeries should be considered in patients with low‐risk disease. Advances in technology have given endoscopic surgery an important role, not only in diagnosis, but also in treatment. Although platinum‐based combination chemotherapy is efficacious in advanced or metastatic disease, current established chemotherapy regimens are toxic and lack a sustained response. Immune checkpoint inhibitors have led to a new era of treatment for advanced or metastatic urothelial carcinomas. The remarkable results achieved thus far show that immunotherapy will likely be the future treatment paradigm. The combination of immune checkpoint inhibitors and other agents is another inspiring avenue to explore that could benefit even more patients. With respect to the high incidence rate and different clinical appearance of upper tract urothelial carcinomas in Taiwan, a possible correlation exists between exposure to certain external risk factors, such as arsenic in drinking water and aristolochic acid in Chinese herbal medicine. As more gene sequencing differences between upper tract urothelial carcinomas and various disease causes are detailed, this has warranted the era of individualized screening and treatment for the disease.

show abstract

Oncological outcomes of laparoscopic nephroureterectomy versus open radical nephroureterectomy for upper tract urothelial carcinoma: An European Association of Urology Guidelines systematic review

Cited by 3 publications

References 0 publications

Clinical outcome of laparoscopic versus robot-assisted radical cystectomy for patients with bladder cancer: a retrospective study

Clinical outcome of laparoscopic versus robot-assisted radical cystectomy for patients with bladder cancer: a retrospective study

Radiation Therapy in Carcinomas of the Renal Pelvis and the Ureters

Recent advances in upper tract urothelial carcinomas: From bench to clinics

Contact Info

Product

Resources

About